Abstract We report a multicenter study of Chinese children in Hong Kong with systemic lupus erythematosus (SLE) nephritis. Children were included if: they fulfilled the ACR criteria, had significant proteinuria or casturia, were Chinese and younger than 19 years and had been diagnosed with SLE between January 1990 and December 2003. Investigators in each center retrieved data on clinical features, biopsy reports, treatment and outcome of these patients. There were 128 patients (eight boys, 120 girls; mean age: 11.9±2.8 years). About 50% presented with multisystem illness and 40% with nephritic/nephrotic symptoms. Negative anti-dsDNA antibodies were found in 6% of the patients. Renal biopsy revealed WHO Class II, III, IV and V nephritis in 13 (10%), 22 (17%), 69 (54%) and 13 (10%) patients, respectively. The clinical severity of the nephritis did not accurately predict renal biopsy findings. The followup period ranged from 1 to 16.5 years (mean±SD: 5.76± 3.61 years). During the study five patients died (two from lupus flare, one from cardiomyopathy, two from infections). Four patients had endstage renal failure (ESRF) (one died during a lupus flare). All deaths and end-stage renal failure occurred in the Class IV nephritis group. Chronic organ damage was infrequent in the survivors. The actuarial patient survival rates at 5, 10 and 15 years of age were 95.3, 91.8, and 91.8%, respectively. For Class IV nephritis patients, the survival rates without ESRF at 5, 10, and 15 years were 91.5, 82.3 and 76%, respectively. The survival and chronic morbidity rates of the Chinese SLE children in the present study are comparable to those of other published studies.
Introduction
Systemic lupus erythematosus (SLE) is the commonest autoimmune disorder with renal involvement that leads to chronic kidney disease. About 10-15% of all SLE patients are diagnosed in childhood [1] . Childhood-onset SLE patients have been reported to differ from their adult-onset counterparts in that they have more nephritis, more central nervous system involvements [2] , and more thrombotic thrombocytopenic purpura (TTP) [3] . In addition, some authors have reported a poorer outcome in pediatric SLE patients [4] , while others did not observe this difference [5, 6] . There have also been reports of ethnic differences in the incidence and severity of SLE patients, indicating that African Americans and Hispanic patients are more prone to the disorder and have more severe symptoms than Caucasian patients [7] [8] [9] . However, most of these reports were small case-series and limited by referral bias as they came from tertiary pediatric centers. To date, very little data are available on SLE nephritis in the Chinese population, and the data that are available are mostly on adult Chinese patients [10] [11] [12] , with only one 10-year-old report on Chinese children [13] . The aim of the present study was to provide updated data on SLE nephritis in Chinese children by investigating a territory-wide cohort of unselected pediatric patients in Hong Kong. In addition to the clinical features and treatment, the mortality and long-term morbidity of these children are also reported.
Patients and Methods
Hong Kong has a total population of 6.7 million inhabitants, of which 95% are Chinese and 21.7% are 18 years of age or younger. Since 1990, all public hospitals fall under the jurisdiction of the Hospital Authority of Hong Kong; consequently, this Hospital Authority provides 90-94% of all patient services in the territory. All 11 pediatric units in Hospital Authority hospitals participated in this retrospective study. Patients diagnosed to have SLE nephritis between January 1, 1990 and December 31, 2003 were retrieved from hospital/departmental databases and cross-checked with renal pathology databases. Patients were included in the study if: (1) they were Chinese and diagnosed with SLE before their 19th birthday; (2) they fulfilled the American College of Rheumatology criteria for diagnosis of SLE; (3) they had persistent significant proteinuria (urine protein/creatinine ratio of 0.5 mg/mg or more) or had active urine sediments with erythrocytes and casts; (4) there was at least 1 year of follow-up data available. In order to meet our aim of reviewing only a homogeneous Chinese cohort, we excluded patients of other ethnicity from the study.
The record of each patient was reviewed, and data were extracted into a standard questionnaire. The data collected included age at first presentation, at diagnosis and at onset of nephritis; the clinical features and worst laboratory results within 3 months of diagnosis; the renal biopsy reports; induction and maintenance treatment and their response; the clinical and renal status at 1 year after nephritis, their complications and outcome at last follow-up.
Hematuria was defined as a positive haemastix or ten erythrocytes per high-power field on urine microscopy on three separate occasions. Proteinuria was defined as a urine protein to creatinine ratio (in milligrams per milligram; Up/c) of 0.2 or more on three separate occasions. Glomerular filtration rate (eGFR) was estimated by the Schwartz formula from body height and serum creatinine. Nephrotic syndrome was defined as the presence of edema, massive proteinuria (Up/c>2) and hypoalbuminemia (serum albumin <25 g/L). Nephritic syndrome was defined by hematuria, hypertension and renal impairment with eGFR <90 ml/min per 1.73 m 2 . Hypertension was defined as the persistent elevation of blood pressure above the 95th percentile for age and gender, and those requiring antihypertensive treatment. Antinuclear antibody (ANA) was measured by indirect immunofluorescence, and a titer of 1/80 or higher was reported as positive. Anti-double strand DNA antibodies (anti-dsDNA) was measured by the enzyme-linked immunosorbent assay (ELISA) using commercial kits and judged to be positive when it was above the quoted reference ranges. All samples for anti-Ro, La, and Sm antibodies were measured by counter-current immunoelectrophoresis in a single university laboratory with in-house reference sera characterized by comparison with CDC reference sera for the respective antibody. Anticardiolipin IgG and IgM were studied by ELISA with the upper limits of normal taken as 15 GPL/ml for IgG and 13 MPL/ml for IgM.
All renal biopsy specimens were examined by light microscopy with standard staining, immunofluorescence and electron microscopy. These were interpreted by renal pathologists in individual hospitals and were classified according to the World Health Organization (WHO) [14] : Class II being mesangial glomerulonephritis; Class III, focal proliferative glomerulonephritis; Class IV, diffuse proliferative glomerulonephritis; Class V, membranous nephropathy. For the purpose of analysis of the presenting features and outcome, mixed Class III+V and Class IV+V nephritis were grouped as Class III and Class IV, respectively, while Class II+V nephritis was grouped with pure Class V nephritis.
Patients were categorized according to the induction therapy they had received for their nephritis: In Group 1, high-dose prednisolone at 2 mg/kg per day was given until remission. In Group 2, patients received high-dose prednisolone plus azathioprine (AZA) at 1-3 mg/kg per day as tolerated. Group 3 patients were treated with high-dose prednisolone plus oral cyclophosphamide (POCYC) at 2 mg/kg per day for 3-6 months. Group 4 patients received high-dose prednisolone plus monthly intravenous cyclophosphamide (IVCYC) pulses at 500-1000 mg/m 2 for 6 months. In Group 5, high-dose prednisolone plus mycophenolate mofetil (MMF) at 750-1200 mg/m 2 per day were given. Group 6 patients received high-dose prednisolone plus cyclosporine A (CSA) at 3-5 mg/kg per day. In all groups, oral prednisolone doses were tailed down gradually as maintenance therapy. Group 3 patients were switched to azathioprine, while Group 4 patients received either quarterly IVCYC for 2 years or MMF or AZA as maintenance. Patients in other groups also received the same induction cytotoxic agent for maintenance.
The renal status at 1 year after onset of nephritis was described as: complete remission (CR; having no clinical symptoms of activity, Up/c<0.2, normal serum albumin and eGFR); partial remission (PR; remission of clinical symptoms, >50% improvement in Up/c or eGFR); nonresponse (NR; no change in clinical status and <50% improvement in Up/c or eGFR). Relapses were defined as recurrences of clinical disease and the worsening of C3/C4 and serology, thereby requiring clinicians to increase therapy to high-dose prednisolone (1 mg/kg per day) or adding another immunosuppressive drug for control. Additional drugs used for relapsers were recorded.
The clinical activity at diagnosis and 1 year after nephritis was assessed by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) [15] . The SLEDAI is a weighted, cumulative index and has 24 attributes grouped into nine organ systems. Each attribute -when present within 10 days prior to the assessment time -was given a certain score. The overall index is the sum of all scores and may range from 0 to 105, with 0 being no disease activity. The chronic morbidity at 1 year and at the last follow-up was assessed using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) [16] . The SDI consists of 41 items in 12 different domains, and it measures irreversible damage because each item is given a score when present for at least 6 consecutive months. The total SDI score can range from 0 to 47, with 0 being no chronic damage. The SDI has recently been applied to childhoodonset SLE patients and found to have face, content and construct validity [17] . The project was approved by various Cluster Ethics and Research Committees of the Hospital Authority.
Statistical analysis
The incidence of lupus nephritis was estimated by dividing the number of new cases by the estimated childhood population aged 0-18 years (as person-years of the at-risk population, obtained from Census and Statistics Department of Hong Kong Government) over the period of interest. The average incidences of lupus nephritis were calculated for each of four 3-year periods, 1992-1994, 1995-1997, 1998-2000 and 2001-2003 , to show the changing trend of incidence over the past decade.
Summary statistics of all data are presented as the mean±SD or range or frequency distribution. Survival data are presented as Kaplan-Meier survival curves. Differences between subgroups were tested for statistical significance by log-rank tests. Multiple logistic analysis of the risk factors for death/endstage renal failure (ESRF) was performed using the Cox proportional hazard model. SPSS ver. 10.0 (SPSS Inc., Chicago, Ill.) was used for statistical analysis.
Results
Our search identified 128 children with SLE nephritis within this 14-year period, all of whom were ethnic Chinese. The study cohort comprised 120 girls and eight boys, with ages at diagnosis ranging from 3.6 to 18.6 years (mean±SD 11.9±2.8 years). The age and sex distributions are shown in Table 1 The disease presentations of the children studied fell primarily into two patterns. Sixty-five patients (50.8%) had multisystemic symptoms of prolonged fever, polyarthritis and skin rash, while renal involvements were indicated by urinary abnormalities only. In 51 patients (40%), the presence of nephrotic or nephritic features brought them to seek medical attention before the diagnosis of SLE. Other rare presenting features were immune thrombocytopenic purpura (two patients), autoimmune hemolytic anemia (two patients), pANCA-positive crescentic glomerulonephritis (one patient), deep vein thrombosis (two patients), renal arterial and venous thrombosis (one patient), Raynaud's phenomenon (one patient), intestinal vasculitis with intestinal bleeding, abdominal pain and ascites (one patient). The patient with pANCA crescentic glomerulonephritis first presented at the age of 11 years with proteinuria, microhematuria and renal impairment. She was positive for antinuclear antibody but negative for antidsDNA. She had strongly positive ANCA (perinuclear pattern) and an anti-myeloperoxidase titer. Renal biopsy revealed fibrocellular crescents in all six glomeruli observed, with immunofluorescent staining showing weak IgG, C3 and C1a staining and negative IgA and IgM staining. She was treated with pulse methylprednisolone followed by oral prednisolone and cyclophopshamide/azathioprine maintenance for 3 years. There was an initial response, but she relapsed at 15 years of age with full blown nephrotic syndrome, Coomb's positive hemolytic anemia and positive ANF and anti-dsDNA. Repeated renal biopsy showed diffuse proliferative glomerulonephritis with full-house immunofluorescence staining. Diagnosis of SLE was usually made within 3 months of the onset of symptoms, but there was a delay of 3-12 months in nine patients and of more than 1 year in 13 patients, especially in those with the more rare presenting features. Evidence of renal involvement was present at diagnosis in 92 patients, and developed within the first year of diagnosis in an additional 19 patients. However, in 17 patients, nephritis occurred more than 1 year after diagnosis of SLE. Tables 2 and 3 show the prevalence of various clinical features and significant laboratory tests within 3 months of SLE diagnosis in this cohort. Of special interest were the eight patients (6%) who had no detectable anti-dsDNA antibodies (sero-negative lupus). While anti-cardiolipin antibodies were prevalent in the study cohort (50.6% for IgG and 38.8% for IgM), lupus anti-coagulants were rare (positive in 17.4%), and clinical thrombosis occurred in only four patients. Three of these patients had typical SLE features, including malar rash, leucopenia and thrombocytopenia, hematuria and proteinuria, positive ANF and antidsDNA, and they developed deep vein thrombosis over the lower limbs 8 months before diagnosis (1), at diagnosis (1) and 5 years after SLE diagnosis (1). They all had positive anticardiolipin and lupus anticoagulant antibodies. The fourth patient presented with polyarthritis, pleural effusion, Coomb's positive hemolytic anemia, thrombocytopenia and gross hematuria. Ultrasound scan and Doppler revealed right kidney enlargement and artery and vein thrombosis. Her renal biopsy also yielded necrotic renal tissue suggestive of infarction. She also had positive antidsDNA and lupus anticoagulant antibodies.
TTP was evident at SLE diagnosis in four patients. All of them had systemic SLE features, blood and renal involvement and positive ANF and anti-dsDNA antibodies. TTP was diagnosed in these patients because of the features of micro-angiopathic hemolytic anemia on peripheral smear examination, thrombocytopenia and renal impairment. The renal biopsy also showed fibrin thrombi in some arterioles in addition to diffuse proliferative glomerulonephritis and full-house immunofluorescence staining. Table 4 shows that Class IV nephritis was the most common renal pathology, followed by Class III, V and II nephritis. There was a general trend that Class IV and V nephritis were associated with more severe renal manifestations with nephrotic syndrome or renal impairment. However, a significant proportion of patients with urinary abnormalities (38.9%) or those with normal eGFR and non-nephrotic-range proteinuria (28.6%) also had Class IV nephritis on initial biopsy. If patients with these renal manifestations were not subjected to renal biopsy, 15-30% of Class IV nephritis would have been missed. Table 5 shows the variety of induction treatments that patients with different renal pathologies had received, and Table 6 shows their renal status at 1 year, relapses, the need for additional treatment and outcome at last follow-up. All of the cases ending in death or ESRF occurred in Class IV patients. Among the Class IV patients, those treated with prednisolone alone or prednisolone plus POCYC had a greater need for additional therapies and more severe renal sequelae (ESRF or impaired eGFR), while in patients treated with IVCYC the nephritis was well under control but more deaths were related to treatment. The duration of follow-up ranged from 1 to 16.5-years with a median of 5.3 years (mean±SD: 5.76±3.61 years). Twenty-four patients were followed up for 10 or more years. Five (3.9%) patients died during the study. One of these was a patient with Class IV nephritis who was treated with prednisolone alone in the earlier years. She had poorly controlled nephritis despite subsequent additional treatment with POCYC and died with multiorgan failure in a lupus flare 2.6 years after diagnosis. A second patient had Class IV nephritis which was well controlled after IVCYC treatment but at 3.1 years after the initial diagnosis he died suddenly due to myocarditis and cardiac tamponade during an acute flare. There were two deaths from infection; both patients had Class IV nephritis treated with a IVCYC regime. One died of tuberculous meningoencephalitis at 5.3 years after diagnosis and the second died of septicaemic shock at 9.8 years after diagnosis. Both had massive proteinuria although a normal eGFR at the time of death.
The fifth patient initially had Class V nephritis but subsequently developed crescentic Class IV nephritis despite POCYC induction. She had renal failure with eGFR 15 ml/min per 1.73 m 2 at 5.5 years after diagnosis, when she opted for hematopoietic stem cell transplantation. However she died of cyclophosphamide-related cardiomyopathy during the conditioning phase.
Overall the patient survival rates at 5 years, 10 years and 15 years post-diagnosis of SLE were 95.3, 91.8 and 91.8% respectively. The 5-year, 10-year and 15-year renal survival rates (survival without ESRF) were 94.1, 87.4 and 81.7, respectively. For Class IV nephritis patients, the 5-year, 10-year and 15-year renal survival rates were 91.5, 82.3 and 76%, respectively. There were no statistical differences in renal survival rates between different WHO classes of the initial biopsy (Fig. 1) . Analysis using the Cox proportional hazard model was performed with the outcome of death/ ESRF and prognostic variables including sex, age at nephritis, persistent hypertension, Up/c and eGFR at presentation, presence of Class IV nephritis, presence of membranous components in biopsy, induction therapy, Of the 123 survivors, 79 patients (64.2%) had no chronic organ damage at their last follow-up. Twenty-seven patients (22%), eight patients (6.5%) and nine patients (7.3%) had a SDI of one, two and more than two respectively. Table 7 showed the organ-system distribution of SDI scores. The commonest organ damages occurred in the renal and musculoskeletal systems and in the eyes. ESRF occurred in three survivors (in addition, one patient who died also had ESRF). Two patients had renal impairment with eGFR <50 ml/min per 1.73 m 2 , and 16 had nephrotic-range proteinuria. Nine patients (7.3%) developed avascular necrosis (AVN) (eight had AVN of both femoral heads and one had AVN of the talus). Cataracts were detected in 17 patients although all were partial (13.8%). Significant neurological sequelae and osteoporosis with fractures each occurred in only 1-2% of the survivors. Table 8 presents the infectious complications reported in our patients. Although infections were infrequent with only 53 episodes reported in 810 patientyears of follow-up (giving an incidence of 0.65 episodes One death case also had ESRF; hence, total number of bad outcomes was seven in Class IV nephritis and eight in the whole group c This patient had transformed to Class IV nephritis, also needed plasmapheresis and hematopoietic stem cell transplant but died Fig. 1 Kaplan-Meier survival curves for renal survival of patients in each WHO class per 10 patient-years), some infections were life-threatening and accounted for two deaths in our cohort.
Discussion
This study provided us with useful information on the epidemiology, clinical features, clinicopathological correlation, treatment and outcome of an unselected cohort of Chinese children with SLE nephritis. We believe that the study cohort is representative of the local Chinese population because it comprised a good sized sample of 128 children over a 14-year period. The participating medical units included all hospitals that together provide more that 90% of both secondary and tertiary care to children in Hong Kong, thus avoiding the selection bias commonly encountered in previously published reports from tertiary centers.
In this Chinese cohort lupus nephritis occurred before the age of 10 years in 23% of the children (rare before 5 years), and between 10 and 15 years of age in 70%. This result is in agreement with the data collected on 556 children in the Pediatric Rheumatology International Trial Organization (PRINTO) which showed that 23% of childhood SLE had onset before 10 years of age [3] . Our cohort had a female to male ratio (F:M) of 2:1 in children younger than 5 years and a 7.7:1 ratio in the 5-to 10-year age group. This ratio is similar to that reported by Cassidy and Petty [20] (F:M, 4:3), King et al. [18] (F:M, 3:1) and the recent PRINTO data [3] (F:M, 5.3:1). However, for patients older than 10 years, the F:M ratio of 20.8:1 in our cohort was much higher than that of 5:1 reported by Cassidy and Petty [20] , the 5.8:1 by the PRINTO dataset [3] or the 10:1 reported by King et al. [18] . This indicates the extreme rarity of male SLE in Chinese teenagers.
The overall incidence of SLE in all age-groups has been estimated to range from 1.9 to 8.7 per 100,000 persons [19] . In the review by Cassidy and Petty, the incidence of SLE in children younger than 15 years was estimated to be 0.36-0.9 per 100,000 persons based on studies carried out in the 1970s [20] . We found the incidence of SLE nephritis in Chinese children to range from 0.47 to 0.93 per 100,000 person-years. However, these figures are not directly comparable as SLE nephritis is only a subset of all SLE patients. Another interesting finding in the present study was that the incidence had doubled between 1992 and 2003. This could be due to a better recognition and documentation of renal involvement in SLE children, or it could be a genuine increase in the incidence of SLE nephritis in the Chinese pediatric population. Roughly the same proportions of children presented with either the typical multi-system features of SLE (with nephritis indicated by urinary abnormalities only) or fullblown nephrotic or nephritic features. Correlation with biopsy findings reiterated the general concept that the clinical presentations could not always predict WHO histopathologic classes. Hence, renal biopsy should form part of the assessment in deciding on therapy for patients with any renal involvement. If renal biopsy had not been performed in patients with only urinary abnormalities or in those with normal eGFR and non-nephrotic proteinuria, a significant proportion of Class IV nephritis may have been missed. Although prior immunosuppressive treatment might have modified the clinical manifestations, this was not likely to have been the case in our patients because most of them underwent renal biopsy at the diagnosis of SLE before the start of any therapy.
Since this was a territory-wide cohort, our review provides a fair estimate of the prevalence of seronegative lupus (6%), concurrent TTP (3%), and antiphospholipid syndrome (3%) in childhood lupus nephritis. TTP is a recognized association of SLE. Brunner et al. reviewed 35 patients with childhood-onset TTP and found that 17 (49%) subsequently received the diagnoses of definite or incipient SLE [21] . However, TTP was not included as a complication or association in several large series of childhood SLE [5, 13, 22] . The prevalence of anticardiolipin antibodies in adult patients with SLE ranged from 12 to 30%, and that of lupus anticoagulants ranged from 15 to 34%. After 20 years of follow-up, 50-70% of these patients developed into antiphospholipid syndrome [23] . Our data indicated a higher prevalence (30-50%) of anticardiolipin antibodies but a lower percentage (3% of the cohort or 10% of those with positive anticardiolipin antibodies) developed into antiphospholipid syndrome with genuine thromboembolism. However, this may be an underestimate since more patients may develop thrombosis on further follow-up.
The treatment recommendations for adult SLE nephritis are well founded on good-quality randomized controlled trials [24] . In children, however, data from randomized clinical trials are nonexistent, and treatment recommendations have been extrapolated from adult studies or derived from past reports of case series. Most investigators have suggested steroid plus POCYC or IVCYC as the standard therapy for Class IV nephritis, but some authors have reported good results with steroid plus AZA, and they could not demonstrate any difference between AZA and CYC therapy [25] [26] [27] . Although our data were retrospective and non-randomized, we observed that all patients who died or developed ESRF (except one death) had Class IV nephritis at the onset of the disease. Those patients who received steroid alone had the worst outcome. While patients treated with POCYC developed ESRF, those treated with IVCYC died of complications resulting from the therapy (infections and cyclophosphamide cardiomyopathy). This was not observed in a report of adult Chinese SLE patients in which POCYC was found to be more effective -but more toxic -than IVCYC regimes [28] . Multivariate analysis, however, did not show any statistically significant differences in renal survival between different biopsy classes or different therapy, probably because of the small number of deaths/ESRF involved.
The prognosis of SLE nephritis in children has improved over the past three decades. In 1968, Meislin et al. [4] reported a 5-year patient and renal (alive without ESRF) survival rate of 43%. In the 1990s, the 5-year patient and renal survival rates reported for SLE nephritis were 78 and 56% by McCurdy et al. [29] or 82.8% and 44.4% by Baqi et al. [26] . A recent publication by Hagelberg et al. in 2002 [25] reported 5-, 10-and 15-year patient survival rates to be 97, 95 and 90%, respectively. In our study, the patient survival rates were 95.3% at 5 years and 91.8% at 10 years, while the renal survival rates were 94.1% at 5 years and 87.4% at 10 years. These figures are comparable to those reported by Hagelberg et al. [25] , Emre et al. [30] and Bogdanovic et al. [31] . Our series had 5-year patient and renal survival rates similar to those reported by Yang et al. in 1994 [13] for a Taiwanese cohort: 95.3 and 91.8% in our series versus 93.1 and 91.1% reported by Yang et al., respectively. However, our Class IV nephritis patients had a better survival rate than their patients (91.5 versus 82% at 5 years). We also had longer follow-up data (10 and 15 years). However, there is a gap of 10 years between the two reports, and our series included unselected patients of all severity, while their patients were from a tertiary referral centre. When compared with adult Chinese patients, our series had a slightly better outcome. In 1999, Mok et al. [10] analyzed the outcome of adult Chinese SLE nephritis patients from the same community as ours. These investigators reported patient survival rates of 98.8, 94.% and 94.4% at the 5-, 10-and 15-year follow-ups, respectively, while the renal survival rates were 92.1, 81.2 and 75.2% at the 5-, 10-, and 15-year follow-ups, respectively. For Class IV nephritis adults, the renal survival rates were 89.1, 71.1 and 61.4% at the 5-, 10-and 15-year follow-ups, respectively [10] . Data on chronic morbidity of SLE nephritis children are scarce in the literature, especially data using standardized scoring systems such as the SDI. In our study, 13.8% of the survivors had two or more SDI at the last follow-up. This percentage is much lower than the incidence of 51% of patients having an SDI of >2 in the report by Miettunen et al. [32] . Compared with their series, our patients also had less chronic morbidity in the neuropsychiatric, cardiovascular or peripheral vascular systems.
In summary, we describe here a representative cohort of Chinese children with SLE nephritis living in Hong Kong. Relative to the incidence values presented previously, SLE nephritis was rare in the Chinese boys of our cohort, especially in teenage boys. About one half presented as multisystem disease and the other half presented with predominantly renal manifestations. On initial renal biopsy, 70% of the patients had Class III and IV nephritis. Our experience supports the practice of performing renal biopsy on all SLE patients with evidence of nephritis. Although it was believed that non-Caucasian patients have a worse prognosis, our series of Chinese children had a good medium term survival rate which was similar to that reported previously for the Caucasian population. Nevertheless, death occurred due to lupus flare or infections, which reflected a delicate balance between adequate immunosuppression and over-treatment. Lastly, we describe chronic organ damage in our patients (as the standardized SDI), which was less common in our cohort than has been reported elsewhere. However, renal damage and avascular necrosis of both hips were common longterm complications in our patients.
